Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record.

A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION: A Report Of The European Anti-ICAM-1 Renal Transplant Study Group

Salmela, Kaija, Wramner, Lars, Ekberg, Henrik, Hauser, Ingeborg, Bentdal, ??ystein, Lins, Lars-Eric, Isoniemi, Helena, B??ckman, Lars, Persson, Nils, Neumayer, Hans-Hellmut, J??rgensen, P??l Foyn, Spieker, Claus, Hendry, Bruce, Nicholls, Anthony, Kirste, G??nter, Hasche, Georg · 1999 · Transplantation

Abstract

BACKGROUND: T-cell activation through T-cell receptor engagement requires co-stimulatory molecules and also adhesion molecules such as ICAM-1. Moreover ICAM-1 mediates leukocyte invasion from the blood into tissue during inflammatory processes. In animal studies using mouse monoclonal antibodies against ICAM-1 (enlimomab), renal allograft survival has been improved and reperfusion damage from ischemia reduced. The European Anti-ICAM-1 Renal Transplant Study (EARTS) was a randomized, double-blind, parallel-group, placebo-controlled study lastingl year and performed in 10 transplant centers in Europe. METHODS: A total of 262 recipients of cadaveric kidneys were given either enlimomab or a placebo for 6 days and were given triple immunosuppressive therapy of cyclosporine, azathioprine, and prednisolone. The primary efficacy endpoint was the incidence of the first acute rejection within 3 months, and each event was assessed by a committee including investigators and independent pathologists. RESULTS: There was no significant difference in the incidences of first acute rejection at 3 months between the placebo and enlimomab groups (39% vs. 45%), and enlimomab did not reduce the risk of delayed onset of graft function (DGF) (26% vs. 31%). Neither was there a difference in patient survival (95% vs. 91%) or graft survival (89% vs. 84%) at 1 year. Fatal events occurred in 19 (7%) patients (7 placebo, 12 enlimomab). Clinically, the most important non-fatal adverse events were infections; however, there was no statistically significant difference between the incidences in the two groups (70% vs. 79%). CONCLUSION: Short term enlimomab induction therapy after renal transplantation did not reduce the rate of acute rejection or DGF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-199903150-00015

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 164

Metadata

Authors
Salmela, K., Wramner, L., Ekberg, H., Hauser, I., Bentdal, ?., Lins, L.-E., Isoniemi, H., B??ckman, L., Persson, N., Neumayer, H.-H., J??rgensen, P. F., Spieker, C., Hendry, B., Nicholls, A., Kirste, G., & Hasche, G.
Venue
Transplantation
Published
1999-03
Volume
67
Issue
5
Pages
729-736
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2028965877
Cited by
164
References
0
FWCI
7.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION: A Report Of The European Anti-ICAM-1 Renal Transplant Study Group. https://app.cochat.ai/papers/10.1097/00007890-199903150-00015
The paper
Salmela, K., Wramner, L., Ekberg, H., Hauser, I., Bentdal, ?., Lins, L.-E., Isoniemi, H., B??ckman, L., Persson, N., Neumayer, H.-H., J??rgensen, P. F., Spieker, C., Hendry, B., Nicholls, A., Kirste, G., & Hasche, G. (1999). A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION: A Report Of The European Anti-ICAM-1 Renal Transplant Study Group. Transplantation. https://doi.org/10.1097/00007890-199903150-00015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.